(0.35%) 5 118.00 points
(0.31%) 38 359 points
(0.40%) 15 991 points
(-0.79%) $83.19
(5.51%) $2.03
(0.45%) $2 357.70
(0.50%) $27.67
(3.99%) $958.85
(-0.26%) $0.932
(-0.41%) $10.98
(-0.59%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.90%
@ $64.71
发出时间: 29 Apr 2024 @ 21:30
回报率: -1.89%
上一信号: Apr 27 - 01:12
上一信号:
回报率: -1.30 %
Live Chart Being Loaded With Signals
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases...
Stats | |
---|---|
今日成交量 | 395 583 |
平均成交量 | 2.02M |
市值 | 6.64B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-1.160 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.65 |
ATR14 | $1.552 (2.45%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-25 | Henderson John T | Sell | 10 562 | Common Stock |
2024-04-12 | Malik Fady Ibraham | Sell | 150 | Common Stock |
2024-04-09 | Malik Fady Ibraham | Buy | 28 605 | Common Stock |
2024-04-09 | Malik Fady Ibraham | Sell | 28 605 | Common Stock |
2024-04-09 | Malik Fady Ibraham | Sell | 4 000 | Common Stock |
INSIDER POWER |
---|
-9.66 |
Last 100 transactions |
Buy: 500 434 | Sell: 624 424 |
音量 相关性
Cytokinetics Inc 相关性 - 货币/商品
Cytokinetics Inc 财务报表
Annual | 2023 |
营收: | $7.53M |
毛利润: | $-4.36M (-57.93 %) |
EPS: | $-5.45 |
FY | 2023 |
营收: | $7.53M |
毛利润: | $-4.36M (-57.93 %) |
EPS: | $-5.45 |
FY | 2022 |
营收: | $94.59M |
毛利润: | $-146.23M (-154.59 %) |
EPS: | $-4.48 |
FY | 2021 |
营收: | $70.43M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.68 |
Financial Reports:
No articles found.
Cytokinetics Inc
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。